Moderna’s stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
Short excerpt below. Click through to read at the original source.
The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.
Short excerpt below. Click through to read at the original source.
The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.